Evaluation of a New APTIMA Specimen Collection and Transportation Kit for High-Risk Human Papillomavirus E6/E7 Messenger RNA in Cervical and Vaginal Samples
- 1 June 2014
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Sexually Transmitted Diseases
- Vol. 41 (6), 365-368
- https://doi.org/10.1097/olq.0000000000000125
Abstract
An APTIMA specimen collection and transportation (SCT) kit was developed by Hologic/Gen-Probe. To compare cervical SCT samples to PreservCyt and SurePath samples and self-collected vaginal samples to physician-collected vaginal and cervical SCT samples. To determine ease and comfort of self-collection with the kit. Each woman (n = 580) self-collected a vaginal SCT, then filled out a questionnaire (n = 563) to determine ease and comfort of self-collection. Colposcopy physicians collected a vaginal SCT and cervical PreservCyt, SCT, and SurePath samples. Samples were tested by APTIMA HPV (AHPV) assay. Agreement between testing of cervical SCT and PreservCyt was 91.1% (κ = 0.82), and that of SurePath samples was 86.7% (κ = 0.72). Agreement of self-collected vaginal SCT to physician-collected SCT was 84.7% (κ = 0.68), and that of self-collected vaginal to cervical SCT was 82.0% (κ = 0.63). For 30 patients with CIN2+, AHPV testing of cervical SCT was 100% sensitive and 59.8% specific compared with PreservCyt (96.6% and 66.2%) and SurePath (93.3% and 70.9%). Vaginal SCT sensitivity was 86.7% for self-collection and 80.0% for physician collection. Most patients found that vaginal self-collection was easy, 5.3% reported some difficulty, and 87.6% expressed no discomfort. Cervical samples collected with the new SCT kit compared well to traditional liquid-based samples tested by AHPV. Although there was good agreement between self-collected and physician-collected samples with the SCT, in a limited number of 30 women, vaginal sampling identified fewer with CIN2+ precancerous cervical lesions than cervical SCT sampling. Comfort, ease of use, and detection of high-risk HPV demonstrated that the kit could be used for cervical and vaginal sampling.This publication has 26 references indexed in Scilit:
- Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysisThe Lancet Oncology, 2014
- Comparison of Seven Tests for High-Grade Cervical Intraepithelial Neoplasia in Women with Abnormal Smears: the Predictors 2 StudyJournal of Clinical Microbiology, 2012
- Performance of the Aptima High-Risk Human Papillomavirus mRNA Assay in a Referral Population in Comparison with Hybrid Capture 2 and CytologyJournal of Clinical Microbiology, 2011
- Aptima HPV E6/E7 mRNA Test Is as Sensitive as Hybrid Capture 2 Assay but More Specific at Detecting Cervical Precancer and CancerJournal of Clinical Microbiology, 2011
- Clinical performance of the APTIMA® HPV Assay for the detection of high-risk HPV and high-grade cervical lesionsJournal of Clinical Virology, 2009
- Analytical characterization of the APTIMA® HPV AssayJournal of Clinical Virology, 2009
- Efficiency of the APTIMA® HPV Assay for detection of HPV RNA and DNA targetsJournal of Clinical Virology, 2009
- Papillomaviruses in the causation of human cancers — a brief historical accountVirology, 2009
- Human Papillomavirus DNA versus Papanicolaou Screening Tests for Cervical CancerThe New England Journal of Medicine, 2007
- Human Papillomavirus and Papanicolaou Tests to Screen for Cervical CancerThe New England Journal of Medicine, 2007